The Exactech implant lawsuit landscape has transformed dramatically in 2026 — and not in the way most patients expected. What began as a straightforward mass tort over defective orthopedic implants has evolved into one of the most legally complex product liability scenarios in recent memory, involving a frozen federal MDL, a Chapter 11 bankruptcy exit, and a bombshell February 2026 lawsuit targeting the private equity firm that acquired Exactech for $737 million. If you or a family member received an Exactech knee, hip, or ankle implant, understanding these developments is critical to knowing what your claim may actually be worth — and how it will be resolved.
What Is the Exactech Implant Lawsuit About?
The core of the Exactech implant lawsuit stems from a massive manufacturing defect discovered in implants produced between 2004 and 2021. Exactech’s vacuum-sealed packaging was missing a critical oxygen barrier layer, causing the polyethylene components inside the implants to oxidize prematurely. When implanted in patients, these degraded components wore out far faster than they should have — leading to pain, implant loosening, bone loss, and the need for painful and expensive revision surgeries. The FDA issued a formal safety communication on this issue, and Exactech ultimately recalled over 143,000 implants across its knee, hip, and ankle product lines.
As of May 2026, more than 1,838 patients have active claims pending in federal MDL 3044, alleging they suffered premature device failure directly tied to these defective packaging conditions. For many patients, this meant undergoing a second major orthopedic surgery — with all the associated risks, recovery time, lost wages, and long-term complications that entails. To explore what a defective medical device claim like this may be worth in general terms, patients can use a medical malpractice calculator as a starting-point reference for understanding compensation ranges tied to device-related injuries.
The MDL 3044 Freeze: Where the Federal Cases Stand in 2026
Before Exactech’s bankruptcy filing, MDL 3044 before Judge Nicholas G. Garaufis in the Eastern District of New York was shaping up to be one of the most watched product liability dockets in the country. Bellwether trials — the test cases that typically signal to both sides what full-scale litigation might look like — had been scheduled for 2025. Then, in October 2024, Exactech filed for Chapter 11 bankruptcy protection. Under 11 U.S.C. § 362, an automatic stay immediately halted all civil litigation against the debtor, freezing every pending case in MDL 3044 overnight.
As of July 2026, 1,838 lawsuits remain pending in MDL 3044 with zero bellwether trials completed and no verdicts or court-approved settlements reached. An additional 700-plus cases are pending in Florida state court. The automatic stay means no new cases can be filed against Exactech directly, and no jury trials will proceed in the traditional sense. The entire resolution framework has shifted from the courtroom to the bankruptcy trust process — a significant change with real consequences for how much patients can ultimately recover.
Exactech’s Chapter 11 Exit and the Compensation Trust Framework
The Delaware bankruptcy court approved Exactech’s Chapter 11 sale and liquidation plan in September 2025. Under the plan, most of Exactech’s operating assets were sold off, leaving behind a restructured entity tasked with resolving the wave of product liability claims. As of mid-2026, negotiations are actively focused on establishing a formal compensation trust or structured claims framework that would allow affected patients to submit and resolve their claims once the company fully exits the bankruptcy process. Legal observers and plaintiffs’ attorneys note that the structure of this trust — including how much money is seeded into it and how claims are tiered by injury severity — will be the single most consequential factor in determining real-world recoveries for the tens of thousands of patients with recalled implants.
The challenge for claimants is that bankruptcy trusts typically offer less than what a successful jury verdict might deliver. Patients who underwent painful revision surgeries, suffered significant bone loss, or experienced long-term complications will likely be placed in higher injury tiers, but the overall funding level of the trust will cap what any individual can receive. Attorneys representing Exactech claimants are pushing hard in the trust negotiation process to maximize the total pool of available funds — particularly in light of the February 2026 fraud lawsuit against TPG, which could unlock additional sources of recovery beyond Exactech itself.
The $8 Million DOJ Settlement: What It Proves About Knowledge
One of the most legally significant developments in the broader Exactech litigation was the approval by the Delaware bankruptcy court of an $8 million False Claims Act settlement with the U.S. Attorney’s Office. Of that total, $7.64 million represents the federal government’s share — compensation for Medicare and Medicaid payments made for procedures involving defective Exactech implants that should never have been billed as medically appropriate devices.
The False Claims Act settlement is far more than a financial footnote. It is a formal acknowledgment — backed by the weight of federal law enforcement — that Exactech submitted or caused the submission of claims to federal healthcare programs involving devices the company knew, or should have known, were defective. For plaintiffs in the MDL and the broader trust process, this settlement serves as powerful corroborating evidence that Exactech had knowledge of the packaging defects and continued to market and sell the implants regardless. That knowledge is central to arguments for punitive damages and heightened negligence liability. Attorneys representing patients are expected to rely heavily on the DOJ settlement findings as they press for maximum compensation through the trust framework.
The February 2026 TPG Lawsuit: The Single Biggest Development of the Year
If one development defines the Exactech litigation story in 2026, it is the billion-dollar fraud lawsuit filed in February 2026 by the Exactech Litigation Trust against TPG Inc., its affiliated entities, and individual principals. TPG, the private equity firm that acquired Exactech for $737 million, is now accused of fraudulent conduct in connection with that acquisition and its stewardship of the company.
The lawsuit alleges that TPG and its principals engaged in fraud that directly contributed to — or concealed — the conditions that led to the massive implant recall and the resulting harm to patients. By targeting not just the bankrupt Exactech entity but the deep-pocketed private equity firm behind it, the Exactech Litigation Trust is attempting to pierce the corporate veil and reach assets that are not constrained by the bankruptcy proceeding. This is critical for patients: if the TPG lawsuit succeeds or results in a substantial settlement, it could dramatically increase the total pool of money available to compensate affected claimants — potentially transforming what would otherwise be modest trust payouts into meaningful recoveries.
Private equity firms acquiring medical device companies have faced increasing scrutiny from plaintiffs’ attorneys and regulators in recent years, and the TPG lawsuit may set an important precedent for how future mass tort cases involving PE-backed companies are litigated. For now, the case is in its early stages, but its trajectory will be closely watched by everyone involved in the Exactech litigation ecosystem.
Key Exactech Implant Lawsuit Statistics at a Glance
- 143,000+ implants recalled by Exactech across knee, hip, and ankle product lines
- 1,838 lawsuits pending in MDL 3044 as of May 2026
- 700+ additional cases pending in Florida state court
- $8 million False Claims Act settlement with the U.S. Attorney’s Office, approved by Delaware bankruptcy court, with $7.64 million as the federal share
- $0 in verdicts or settlements reached in ongoing Exactech lawsuits as of July 2026
- $737 million — TPG’s acquisition price for Exactech, now central to the February 2026 fraud lawsuit
- Billions in potential exposure — the Exactech Litigation Trust’s fraud suit against TPG seeks damages in excess of $1 billion
What Patients Should Do Right Now
The complexity of the Exactech situation in 2026 — a frozen MDL, an active bankruptcy trust negotiation, a False Claims Act settlement, and a billion-dollar fraud suit against a private equity firm — makes it more important than ever for affected patients to have experienced legal counsel. Here is what patients with recalled Exactech implants should prioritize:
- Confirm whether your implant was recalled. Not every Exactech device was subject to the recall. Your surgeon or the hospital where your procedure was performed should have records of the specific implant model and lot number used. Cross-reference that information against the FDA recall database.
- Document your medical history thoroughly. Collect all records related to your original implant surgery, any follow-up imaging, your revision surgery if applicable, and any ongoing treatment. The injury tier you are placed in under the compensation trust framework will depend heavily on documented medical evidence.
- Consult a mass tort attorney experienced in medical device litigation. The trust negotiation process is not something patients navigate on their own. An attorney with MDL and bankruptcy trust experience can advocate for your placement in the appropriate injury tier and ensure your claim is properly submitted and protected.
- Understand that timing still matters. Even though the automatic stay has paused direct litigation against Exactech, the trust claim submission process will have its own deadlines. Missing those deadlines could bar your recovery entirely.
- Monitor the TPG lawsuit. If the Exactech Litigation Trust’s fraud suit against TPG results in a significant recovery, it could increase the compensation available to all claimants. Your attorney should be tracking this development closely on your behalf.
Frequently Asked Questions: Exactech Implant Lawsuit in 2026
FAQ 1: Can I still file an Exactech implant lawsuit in 2026?
The automatic bankruptcy stay prevents new lawsuits from being filed directly against Exactech. However, patients with recalled implants can still pursue compensation through the bankruptcy trust claim process, which is expected to be formally established as Exactech completes its exit from Chapter 11. Additionally, the February 2026 fraud lawsuit against TPG represents a separate legal avenue that does not involve filing against the bankrupt entity. Patients should consult with a mass tort attorney immediately to understand their options under both the trust framework and any third-party claims that may be available to them.
FAQ 2: How much compensation can Exactech implant patients expect from the trust?
As of July 2026, no compensation amounts have been finalized and no settlements have been reached. The trust framework is still being negotiated, and the ultimate payout levels will depend on the total funding of the trust, the number of eligible claimants, and how injury tiers are structured. Patients who underwent revision surgeries, experienced significant bone loss, or suffered long-term complications are expected to be placed in higher tiers with larger potential awards. The outcome of the TPG fraud lawsuit could also materially affect total available compensation. Patients should not rely on unofficial estimates circulating online, as these figures are speculative until the trust terms are formally approved.
FAQ 3: What is the February 2026 TPG lawsuit and why does it matter?
The February 2026 lawsuit was filed by the Exactech Litigation Trust against TPG Inc., its affiliated entities, and individual principals. The suit alleges fraud in connection with TPG’s $737 million acquisition of Exactech and its management of the company. Because TPG is not itself in bankruptcy, this lawsuit targets assets outside the constrained bankruptcy estate — meaning a successful outcome could significantly increase the total compensation pool available to patients with recalled implants. It is widely considered the most consequential development in the Exactech litigation in 2026.
FAQ 4: Why have no Exactech MDL bellwether trials taken place?
Bellwether trials in MDL 3044 were scheduled for 2025 but were halted when Exactech filed for Chapter 11 bankruptcy protection in October 2024. The automatic stay under 11 U.S.C. § 362 immediately suspended all civil litigation against the debtor, including the bellwether schedule. As of July 2026, no trials have taken place and none are expected to proceed in the traditional MDL format. The litigation has effectively migrated from the courtroom to the bankruptcy trust resolution process.
FAQ 5: What did the $8 million DOJ settlement reveal about Exactech’s knowledge of defects?
The False Claims Act settlement — approved by the Delaware bankruptcy court with $7.64 million allocated as the federal share — reflects a formal resolution with the U.S. Attorney’s Office over claims that Exactech submitted or caused the submission of false claims to Medicare and Medicaid involving defective implants. While the settlement does not constitute a judicial finding of guilt, it is a powerful indicator that federal investigators concluded Exactech had knowledge of the packaging defects. Plaintiffs’ attorneys are expected to use this settlement as corroborating evidence in support of negligence and punitive damages arguments throughout the trust claims process.
Victoria Chambers is a mass tort and class action research analyst with extensive knowledge of multi-district litigation (MDL), defective product cases, dangerous drug lawsuits, and toxic exposure claims across the United States. Victoria is not an attorney and the information provided is for educational purposes only.